MedTrace Logo

Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B

NCT06618079 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-10-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety.

Conditions

Interventions

DRUG

HUC2-565-A, HUC2-565-A and HUC2-565-B

Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.

DRUG

HUC2-565-B, HUC2-565-A and HUC2-565-B

Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.

Sponsors & Collaborators

  • Huons Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Gyu Park · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-20
Primary Completion
2024-07-12
Completion
2024-10-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06618079 on ClinicalTrials.gov